Pich A, Chiarle R, Chiusa L, Palestro G
Department of Biomedical Sciences and Human Oncology, University of Turin, Italy.
Cancer. 1994 Sep 1;74(5):1568-74. doi: 10.1002/1097-0142(19940901)74:5<1568::aid-cncr2820740512>3.0.co;2-r.
The prognosis of thymoma is related mainly to the tumor stage. The prognostic value of argyrophilic nucleolar organizer regions (AgNORs) has been demonstrated in several human neoplasias. Ninety primary thymomas were investigated retrospectively to assess whether AgNOR analysis could offer additional prognostic information.
Sections from surgically resected thymomas, routinely fixed in formol and embedded in paraffin, were stained with the argyrophilic method of Ploton. The mean number of AgNORs in the nuclei of 100 tumor cells (AgNOR counts) was calculated for each case. The association between AgNOR counts and survival was assessed by means of uni- and multivariate survival analyses.
On univariate analysis, AgNOR counts were associated significantly with 5- and 10-year survival rates (95% and 90%, respectively, for thymomas with 5.58 or fewer AgNORs per cell, but only 55% and 44%, respectively, for tumors with more than 5.58 AgNORs per cell; P < 0.0001). Histologic subtypes of the American classification (P = 0.0006) and clinical stage (P < 0.0001) also were correlated with prognosis. The multivariate survival analysis showed that AgNOR counts (P = 0.001), clinical stage (P < 0.001), and age (P = 0.011) were independent prognostic variables. AgNOR counts were associated with histologic subtypes in the American (P = 0.0001) and European (P = 0.005) classifications and with the clinical stage (P < 0.0001). Moreover, thymoma cells and intermingling lymphocytes showed different numbers of AgNORs and patterns of AgNOR distribution.
Analysis of argyrophilic nucleolar organizer regions provides useful prognostic information for patients with thymomas and offers an exact evaluation of the proliferative activity of the neoplastic cells even for thymomas with prominent lymphocytic infiltration.
胸腺瘤的预后主要与肿瘤分期相关。嗜银核仁组织区(AgNORs)的预后价值已在多种人类肿瘤中得到证实。对90例原发性胸腺瘤进行回顾性研究,以评估AgNOR分析是否能提供额外的预后信息。
手术切除的胸腺瘤标本,常规用甲醛固定并石蜡包埋,采用普洛顿嗜银染色法染色。计算每例100个肿瘤细胞核中AgNORs的平均数(AgNOR计数)。通过单因素和多因素生存分析评估AgNOR计数与生存率之间的关联。
单因素分析显示,AgNOR计数与5年和10年生存率显著相关(每细胞AgNORs为5.58个或更少的胸腺瘤,5年和10年生存率分别为95%和90%,而每细胞AgNORs超过5.58个的肿瘤,5年和10年生存率分别仅为55%和44%;P<0.0001)。美国分类的组织学亚型(P = 0.0006)和临床分期(P<0.0001)也与预后相关。多因素生存分析表明,AgNOR计数(P = 0.001)、临床分期(P<0.001)和年龄(P = 0.011)是独立的预后变量。AgNOR计数与美国(P = 0.0001)和欧洲(P = 0.005)分类的组织学亚型以及临床分期(P<0.0001)相关。此外,胸腺瘤细胞和混杂的淋巴细胞显示出不同数量的AgNORs和AgNOR分布模式。
嗜银核仁组织区分析为胸腺瘤患者提供了有用的预后信息,即使对于淋巴细胞浸润明显的胸腺瘤,也能准确评估肿瘤细胞的增殖活性。